THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only ...
Study Also Shows 36% Reduction in Risk of Heart Attack VESALIUS-CV is a Phase 3, double-blind, randomized, placebo-controlled global clinical trial designed to evaluate the impact of LDL-C lowering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results